Early suPAR-guided anakinra decreases the risk for severe respiratory failure in SARS-CoV-2 pneumonia and restores the pro-/anti-inflammatory balance.

Expression of a Dravet syndrome-associated mutation in inhibitory neurons disrupts activity of brainstem respiratory neurons and diminishes respiratory behavior in conjunction with seizures and premature death.

Patients exposed to ⍺1-AR antagonists have reduced risks of mechanical ventilation and death in lower respiratory tract infection-related illnesses, highlighting the need for prospective trials assessing ⍺1-AR antagonists' effectiveness in COVID-19.

COVID-19 severity, rather than sex or age, predicts SARS-CoV-2 kinetics, and SARS-CoV-2 viral load from lower respiratory tract specimens may predict severe disease days before clinical deterioration for COVID-19 patients.

Atoh1 promotes the development of two different neural circuits involved in hypoxic and hypercapnic respiratory responses that together are essential for neonatal respiratory drive and survival.

Severe COVID-19 is characterised by a plasma proteomic biomarker signature, indicating innate immune activation, leucocyte–endothelial interactions, and epithelial injury.

Mitochondrial respiratory chain dysfunction inhibits mitochondrial one-carbon metabolism, impairing cellular nucleotide biosynthesis.

Current evidence does not suggest adverse effects of ACE inhibitors or ARBs in COVID-19 patients and, to the contrary, discontinuing these drugs in these patients may potentially be harmful.

Tiled-ClickSeq provides a simple and novel next-generation sequencing approach for complete genome sequencing of viruses including SARS-CoV-2, whilst capturing RNA recombination events and minority variants.

Post-acute or long-COVID is associated with bystander T-cell activation and a recurring antimicrobial resistant, bacterial ventilator-associated pneumonia.